BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, September 28, 2023
Home » Blogs » BioWorld MedTech Perspectives » Watching the Watchman and watching FDA

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Watching the Watchman and watching FDA

Oct. 17, 2014
By Mark McCarty
No Comments

Sartorially anachronistic, but you get the point
Different uniform, but he carries a stick, too

There is certainly no shortage of stories (or controversy) in the world of med tech, and here are a couple of stories that kept a lot of people glued to their computer screens (more or less) recently.

FDA watches the Watchman

FDA has heard a third affirmative vote from an advisory committee on the question of the Watchman left atrial appendage closure device, although the vote in favor of the device was close for the second consecutive time. It’s an interesting predicament for the agency because members of the Office of Device Evaluation are clearly uncomfortable with the Watchman, but it’s becoming increasingly difficult for the agency to dismiss the views of physicians.

However unsettling FDA’s misgivings might be, it does not have to go it alone. It has a safety net called the Centers for Medicare & Medicaid Services, which along with FDA provided a case study for inter-agency coordination with their handling of the transcatheter aortic valve (a.k.a., TAVR).

We note, however, that CMS had to cough up more for the Edwards Sapien device within a year of rendering its coverage decision because some perfectly qualified centers couldn’t use the device without losing money. We might reasonably expect the same kind of loopy governmental behavior for the Watchman, which has been available in Europe for how long?

In any event, Boston Scientific won’t have the market to itself for long. St. Jude Medical is working on the second iteration of the Amplatzer device, and these are not the only companies working on this kind of technology. FDA won’t have to watch the Watchman for long.

Industry watches the device classification rule

It’s not often a regulatory writer remembers a med tech draft guidance or proposed rule with a lot of clarity (FDA turns out so many of them). But who can forget the announcement in the March 25 Federal Register for device classification procedures?

There’s a ton in there, and my write-up in the March 26 edition of Medical Device Daily didn’t come close to covering it all. One of the more obvious examples of saber rattling was FDA’s observation that some stakeholders think clinical trials are great special controls for class II devices. I said in my write-up that FDA “has 90 days to take on the near-certain rebellion the rule seems destined to provoke.”

Did I go out on a limb with that observation? Maybe, but the agency extended the comment period to Sept. 22, and there hasn’t been much noise about it in the nearly four weeks that have since passed. The draft rule discusses matters such as a class III device designation based on “heightened potential risk,” which strikes this scribbler as highly elastic language. And that’s far from an exhaustive reading of the document.

It seems unlikely that this proposed rule will just die off gracefully, but it will be trimmed back by quite a bit. A good example of FDA’s regulatory ambitions and the attendant resistance is the guidance for distinguishing between device recalls and improvements. I won’t go into details, but it’s tough to avoid the conclusion that FDA now sees draft guidances and proposed rules as opening gambits in a negotiation.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 27, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 27, 2023.
  • 3D illustration of cancer in crosshairs

    Dato data lack means upside for Gilead; Padcev 'must-win' does win

    BioWorld
    Upbeat phase III findings outweighed less encouraging late-stage trial news, as big pharma provided a mixed bag of cancer findings – with one data batch to form...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
  • Apple Computer Inc. logo

    Apple scores win over Masimo for patents for physiological detectors, but ITC decision awaits

    BioWorld MedTech
    Apple Inc., of Cupertino, Calif., has prevailed over Masimo Corp., in a ruling at the U.S. Court of Appeals for the Federal Circuit, an outcome that invalidated...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing